Valneva SE (VALN)
NASDAQ: VALN · Real-Time Price · USD
5.69
+0.18 (3.27%)
Nov 4, 2026, 11:04 AM EST - Market open
Valneva SE Employees
Valneva SE had 620 employees as of June 30, 2026.
Employees
620
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$263,390
Profits / Employee
-$290,499
Market Cap
543.64M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 620 | - | - |
| Dec 31, 2025 | 674 | -39 | -5.47% |
| Dec 31, 2024 | 713 | 37 | 5.47% |
| Dec 31, 2023 | 676 | -43 | -5.98% |
| Dec 31, 2022 | 719 | -43 | -5.64% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| REGENXBIO | 371 |
| Puma Biotechnology | 179 |
| Neurogene | 131 |
| Crescent Biopharma | 69 |
| Surrozen | 44 |
| Shattuck Labs | 40 |
| DiaMedica Therapeutics | 35 |
| Faeth Therapeutics | 29 |
VALN News
- 21 days ago - Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences - GlobeNewsWire
- 27 days ago - UK Revokes Marketing Authorisation For Valneva's Chikungunya Vaccine IXCHIQ; Shares Slide - Nasdaq
- 27 days ago - Valneva announces Ixchiq marketing authorization revoked by UK MHRA - TheFly
- 27 days ago - VALNEVA SE: Valneva Provides Update on IXCHIQ in the United Kingdom - Finanz Nachrichten
- 27 days ago - Valneva Provides Update on IXCHIQ® in the United Kingdom - GlobeNewsWire
- 2 months ago - Pfizer, Valneva announce EMA validation for PF-07307405 MAA - TheFly
- 2 months ago - Valneva Stock (VALN) Soars Over 20% On Lyme Disease Vaccine Hopes - TipRanks
- 2 months ago - Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency - Business Wire